228 related articles for article (PubMed ID: 30568462)
1. A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis.
Xu L; Yan N; Li Z; Luo L; Wu X; Liu Q; Xu Y; Cao Y
Onco Targets Ther; 2018; 11():8389-8398. PubMed ID: 30568462
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
3. An evidence-based review of the outcome of fulvestrant plus a targeted agent versus fulvestrant alone in treating hormone receptor-positive endocrine therapy-resistant metastatic breast cancer.
Hua YM
Arch Gynecol Obstet; 2019 Nov; 300(5):1377-1382. PubMed ID: 31599350
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
Lin WZ; Xu QN; Wang HB; Li XY
Breast Cancer; 2017 May; 24(3):345-352. PubMed ID: 28324247
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
Ji D; Luo Y; Wang J; Chen S; Lan B; Ma F; Xu B; Fan Y
BMC Cancer; 2023 Aug; 23(1):805. PubMed ID: 37644396
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials.
Chanchan G; Xiangyu S; Fangfang S; Yan C; Xiaoyi G
PLoS One; 2018; 13(9):e0204202. PubMed ID: 30235292
[TBL] [Abstract][Full Text] [Related]
8. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis.
Liu S; Sun X; Xu X; Lin F
J Breast Cancer; 2020 Oct; 23(5):460-483. PubMed ID: 33154823
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.
Xu L; Wu X; Hu C; Zhang Z; Zhang L; Liang S; Xu Y; Zhang F
Onco Targets Ther; 2016; 9():4061-74. PubMed ID: 27445497
[TBL] [Abstract][Full Text] [Related]
12. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
Reinert T; Barrios CH
Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
[TBL] [Abstract][Full Text] [Related]
13. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis.
Zhang T; Feng F; Zhao W; Yao Y; Tian J; Zhou C; Zang C; Liu C; Wang X; Sun C
Cancer Manag Res; 2018; 10():5869-5880. PubMed ID: 30510455
[TBL] [Abstract][Full Text] [Related]
16. Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Li M; Xiong Y; Liao C; He Y; Duan S; Yi F; Wei Y; Zhang W
Breast Cancer Res Treat; 2020 Apr; 180(2):269-278. PubMed ID: 32008124
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
18. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
19. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
20. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F
Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
